nach oben

Erschienen in:

12.11.2019 | Chronisch-entzündliche Darmerkrankungen | FORTBILDUNG . ÜBERSICHT

Praxisnahe Tipps zu Diagnostik und Therapie

Chronisch entzündliche Darmerkrankungen

verfasst von: Prof. Dr. med. Thomas Ochsenkühn, Dr. med. Daniel Szokodi, Dr. med. Cornelia Tillack

Erschienen in: MMW - Fortschritte der Medizin | Sonderheft 3/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapie der chronisch entzündlichen Darmerkrankungen (CED) Morbus Crohn (MC) und Colitis ulcerosa (CU) ist durch den Einsatz von Immunsuppressiva und Antikörpern zwar fundamental effektiver, aber auch anspruchsvoller geworden und daher heute fast ausschließlich in der Hand von CED-Spezialisten. Hausärzte spielen aber eine wichtige Rolle bei der Früherkennung der Erkrankung und der Begleitung der Patienten. Lesen Sie hier einen auf Leitlinien, Studien und Erfahrungswerten basierenden, pragmatischen Überblick über Diagnose und Therapie.

Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779–89.CrossRef

Darfeuille-Michaud A, Boudeau J, Bulois P et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127:412–21.PubMedCrossRef

Tian Z, Liu J, Liao M et al. Beneficial effects of fecal microbiota transplantation on ulcerative colitis in mice. Dig Dis Sci. 2016;61:2262–71.PubMedCrossRef

Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1:164.PubMedCrossRef

Tao Zuo, Siew C. Ng. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front Microbiol. 2018;9:2247.PubMedPubMedCentralCrossRef

Rosenstiel P, Sina C, Franke A, Schreiber S. Towards a molecular risk map—recent advances on the etiology of inflammatory bowel disease. Semin Immunol. 2009;21:334–5.PubMedCrossRef

Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.PubMedPubMedCentralCrossRef

Frolkis A, Dieleman LA, Barkema HW et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol. 2013;27:18–24.CrossRef

Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRef

10.

Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–40.PubMedCrossRef

11.

Faubion WA, Jr, Loftus EV, Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.PubMedCrossRef

12.

Michelassi F, Sultan S. Surgical treatment of complex small bowel Crohn disease. Ann Surg. 2014;260:230–5.PubMedCrossRef

13.

Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.PubMedCrossRef

14.

Preiß JC, Bokemeyer B, Buhr HJ et al. Aktualisierte S3-Leitlinie — „Diagnostik und Therapie des Morbus Crohn” 2014. Z Gastroenterol. 2014;52:1431–84.PubMedCrossRef

15.

Kucharzik T, Dignass AU, Atreya Raja et al. Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol. 2018;56:1087–1169.CrossRef

16.

Gomollon F, Dignass A, Annese V et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn’s and Colitis. 2017;11:3–25.PubMedCrossRef

17.

Panes J, Bouzas R, Chaparro M et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–45.PubMedCrossRef

18.

Tillack C, Seiderer J, Brand S et al. Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn’s disease. Inflamm Bowel Dis. 2008;14:1219–28.PubMedCrossRef

19.

Romkens TE, Kampschreur MT, Drenth JP et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012;18:2190–8.PubMedCrossRef

20.

Wang Y, Parker CE, Bhanji T et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.PubMed

21.

Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.PubMedCrossRef

22.

Williams JG, Alam MF, Alrubaiy L et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.PubMedPubMedCentralCrossRef

23.

Danese S, Fiorino G, Peyrin-Biroulet L et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;20:160:704–11.

24.

Feagan BG, Rutgeerts P, Sands BE et al.: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.PubMedCrossRef

25.

Kotlyar DS, Lewis JD, Beaugerie L et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58.PubMedCrossRef

26.

Beigel F, Steinborn A, Schnitzler F et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf. 2014;23:735–44.PubMedCrossRef

27.

Qiu Y, Mao R, Chen BL et al. Effects of combination therapy with immunomodulators on trough levels and antibodies against TNF antagonists in patients with Inflammatory Bowel Disease: A Meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1359–72.PubMedCrossRef

28.

Jeong DY, Kim S, Son MJ et al. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev. 2019;18:439–54.PubMedCrossRef

29.

Sandborn WJ et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;376:1723–36.CrossRefPubMed

30.

Aschenbrenner D. Tofacitinib trial prompts FDA review of adverse effects. American Journal of Nursing. 2019:119:25.PubMedCrossRef

31.

Sands BE, Han C, Zhang Het al. P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies. ECCO abstract P681; 2019.

32.

Ochsenkühn T, Tillack C, Szokodi D et al. One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis. Journal of Crohn’s and Colitis. 2019;13:298–9.CrossRef

33.

Lunney PC, Kariyawasam VC, Wang RR et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics. 2015;42:61–70.PubMedCrossRef

34.

Hanauer SB, Sandborn WJ, Feagan BG et al. IM-UNITI: 3 year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn’s disease. J Crohns Colitis. 2019; pii: jjz110. doi: https://doi.org/10.1093/ecco-jcc/jjz110. [Epub ahead of print]

35.

Mantzaris GJ. Thiopurines and methotrexate use in IBD patients in a biologic era. Curr Treat Options Gastroenterol 2017;15:84–104.PubMedCrossRef

36.

Jørgensen KK, Olsen IC, Goll GL et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–16.PubMedCrossRef

37.

Ye BD, Pesegova M, Alexeeva O et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699–1707.PubMedCrossRef

38.

Gecse KB, Végh Z, Lakatos PL. Optimizing biological therapy in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2016;10:37–45.PubMedCrossRef

39.

Allen PB, Olivera P, Emery P et al. Review article: moving towards common therapeutic goals in Crohn’s disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017;45:1058–72.PubMedCrossRef

40.

Parragi L, Fournier N, Zeitz J et al. Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. J Crohns Colitis 2018;12:811–18.PubMedCrossRef

41.

Jürgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811–9.PubMedCrossRef

42.

Braun I, Heitland W, Bader F et al. Einfluss des präoperativen Einsatzes von TNF-alpha-Antikörpern auf den peri- und postoperativen Verlauf von CED-Patienten mit Darmresektionen. Z Gastroenterol. 2018;56:e215–6.

43.

Lightner AL, McKenna NP, Alsughayer A et al. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn’s patients. Pediatr Surg. 2019; S0022-3468(19)30015-6. doi: https://doi.org/10.1016/j.jpedsurg.2019.01.006. [Epub ahead of print].PubMedCrossRef

44.

Xu Y, Yang L, An P et al. Meta-Analysis: The influence of preoperative infliximab use on postoperative complications of Crohn’s Disease. Inflamm Bowel Dis. 2019;25:261–9.PubMedCrossRef

45.

Brennan GT, Ha I, Hogan C et al. Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn’s disease patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:997–1002.PubMedCrossRef

46.

Lichtiger S, Present DH. Preliminary report: Cyclosporin in treatment of severe active ulcerative colitis. Lancet;1990;226:16–9.CrossRef

47.

Herrmann KA, Michaely HJ, Seiderer J, Ochsenkuehn T et al. The „star-sign“ in magnetic resonance enteroclysis: a characteristic finding of internal fistulae in Crohn’s disease. Scand J Gastroenterol. 2006;41:239–41.PubMedCrossRef

Titel: Praxisnahe Tipps zu Diagnostik und Therapie
Chronisch entzündliche Darmerkrankungen
verfasst von: Prof. Dr. med. Thomas Ochsenkühn
Dr. med. Daniel Szokodi
Dr. med. Cornelia Tillack
Publikationsdatum: 12.11.2019
Verlag: Springer Medizin
Schlagwörter: Chronisch-entzündliche Darmerkrankungen
Colitis ulcerosa
Morbus Crohn
Erschienen in: MMW - Fortschritte der Medizin / Ausgabe Sonderheft 3/2019
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI: https://doi.org/10.1007/s15006-019-0857-1

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 3/2019

Antikoagulation bei Vorhofflimmern

Wie Fitness schützt

Haben kleinere Menschen ein höheres Diabetesrisiko?

Antihypertensive Therapie bei kritischer Evidenzlage

Psoriasis erhöht Krebsrisiko

Rationale Abklärung und Therapie der Fibromyalgie

Magen-Darm-Erkrankungen in der Hausarztpraxis